| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/29/2004 | WO2004009595A1 Combination therapy with 1,3-dioxolanes and inosine monophosphate dehydrogenase inhibitors |
| 01/29/2004 | WO2004009593A1 Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates |
| 01/29/2004 | WO2004009592A1 Bicyclic unsaturated tertiary amine compound |
| 01/29/2004 | WO2004009588A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 01/29/2004 | WO2004009587A1 Oxazolidinone derivatives as antibacterial agents |
| 01/29/2004 | WO2004009583A2 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor |
| 01/29/2004 | WO2004009582A1 Substituted thiophene carboxamide compounds for the treatment of inflammation |
| 01/29/2004 | WO2004009560A1 Novel bio-active molecules |
| 01/29/2004 | WO2004009550A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 01/29/2004 | WO2004009536A1 Novel compounds as histone deacetylase inhibitors |
| 01/29/2004 | WO2004009123A2 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 01/29/2004 | WO2004009121A1 Pharmaceutical compositions comprising hepatitis c viral protease inhibitors |
| 01/29/2004 | WO2004009120A1 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| 01/29/2004 | WO2004009104A1 Megasphaera elsdenii strain and its uses |
| 01/29/2004 | WO2004009103A1 Probiotics for gut neuromuscular functions |
| 01/29/2004 | WO2004009099A1 Phosphorylated dextran |
| 01/29/2004 | WO2004009084A1 Methods of treating infection using antibiotics and glycogen phosphorylase inhibitors |
| 01/29/2004 | WO2004009061A2 Bioavailability/bioefficacy enhaning activity of cuminum cyminum and extracts and fractions thereof |
| 01/29/2004 | WO2004009021A2 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/29/2004 | WO2004009020A2 Pyrrolopyrimidine thionucleoside analogs as antivirals |
| 01/29/2004 | WO2003101996A3 Esters in position 20 of camptothecins |
| 01/29/2004 | WO2003088748A8 Use of heme oxygenase-1 and products of heme degradation |
| 01/29/2004 | WO2003065980A3 Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin |
| 01/29/2004 | WO2003053971A8 Pyridoquinoxaline antivirals |
| 01/29/2004 | WO2003050241A3 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 01/29/2004 | WO2003048184A3 Flavivirus ns1 subunit vaccine |
| 01/29/2004 | WO2003040080A3 Lipoxin a4 analogs |
| 01/29/2004 | WO2003035001A3 Anti-hsv agent for inhibiting replication of hsv-1 and hsv-2 and method of producing a substance having anti-hsv activity |
| 01/29/2004 | WO2003032905A3 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 01/29/2004 | WO2003015709A3 Bifunctional glycopeptides antibiotics and combinatorial libraries thereof |
| 01/29/2004 | WO2003000180A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/29/2004 | WO2002090503A3 Anti-microbial peptides and compositions |
| 01/29/2004 | WO2002078631A3 Improved conditionally replicating vectors for inhibiting viral infections |
| 01/29/2004 | WO2002072794A3 Immunoglobulin superfamily proteins |
| 01/29/2004 | US20040019232 Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction |
| 01/29/2004 | US20040019214 Carbocyclic carbo, oxo amines such as N-heptyl-3-methyl-4-oxo -1,4-dihydroquinoline-2-carboxamide, used for prophylaxis of gastrointerstinal disorders |
| 01/29/2004 | US20040019211 Crystal structured fungicides selected from itraconazole, posaconazole or saperconazole used for prevention or prophylaxis of fungi, yeasts and dermatophyte infections |
| 01/29/2004 | US20040019210 Kinase inhibitors |
| 01/29/2004 | US20040019203 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
| 01/29/2004 | US20040019181 Antimicrobial cationic peptides |
| 01/29/2004 | US20040019117 Anti tubercular drug: compostions and methods |
| 01/29/2004 | US20040019111 A new use of existing pharmaceutical, a nonsteroidal antiinflammatory agents |
| 01/29/2004 | US20040019106 Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase |
| 01/29/2004 | US20040019105 Compounds with stabilized S-nitrosyl group and a free alcohol or a free thiol; nitric oxide (no) releasing; bacteristats |
| 01/29/2004 | US20040019103 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof |
| 01/29/2004 | US20040019084 Nitric oxide synthase inhibitors; antioxidant regenerants |
| 01/29/2004 | US20040019072 Dimer-selective RXR modulators and methods for their use |
| 01/29/2004 | US20040019059 Drugs such as N-(4-benzoylphenyl)-4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxamide, used as antiinflammatory or antiarthritic agents |
| 01/29/2004 | US20040019052 5-(2,3-Difluorophenyl)-1H-pyrazolo(3,4-c)pyridazin-3-ylamine, e.g.; an enzyme inhibitor of GSK-3, a serine/threonine protein kinase; neuroprotectants in treatment of acute stroke, neurotraumatic injuries and diabetic conditions |
| 01/29/2004 | US20040019048 Imidazo(4,5-c)quinoline and the 6,7,8,9-tetrahydro derivative having urea, thiourea, acylurea or sulfonylurea at the 1-position as immune response modifiers; biosynthesis of cytokines; viricides; antitumor, -carcinogenic agents |
| 01/29/2004 | US20040019046 Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| 01/29/2004 | US20040019038 Compounds useful as anti-inflammatory agents |
| 01/29/2004 | US20040019029 Manzamines for treatment of drug resistant infection |
| 01/29/2004 | US20040019012 A therapeutic drug suitable for topical administration to an eye, containing an antibiotic for gram-positive bacterial infection, a cyclodextrin compound to maintain drug in solution and cetylpyridium chloride |
| 01/29/2004 | US20040018994 3-Descladinosyl-6-O-carbamoyl and 6-O-carbonoyl macrolide antibacterial agents |
| 01/29/2004 | US20040018986 Viricide against hepatitis virus |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018963 O-derivatized nocathiacin derivatives |
| 01/29/2004 | US20040018558 Method for identifying modulators of G protein coupled receptor signaling |
| 01/29/2004 | US20040018557 High speed elimination of immunoglobulins from human body |
| 01/29/2004 | US20040018514 Nucleotide sequence derived from Listeria inocua |
| 01/29/2004 | US20040018508 Surrogate antibodies and methods of preparation and use thereof |
| 01/29/2004 | US20040018242 Nanoparticulate nystatin formulations |
| 01/29/2004 | US20040018190 Drugs and foods improving the quality of life and process for producing the same |
| 01/29/2004 | US20040018184 Administering mixtures of monocytes and drugs selected from taxanes, alkaloids, antibiotics or enzyme inhibitors, as anticarcinogenic agents |
| 01/29/2004 | US20040018177 Vacination method |
| 01/29/2004 | US20040018150 Screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for |
| 01/29/2004 | CA2493406A1 Gm-negative ehv-mutants without heterologous elements |
| 01/29/2004 | CA2493255A1 Probiotics for gut neuromuscular functions |
| 01/29/2004 | CA2493227A1 Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates |
| 01/29/2004 | CA2492922A1 Substituted thiophene carboxamide compounds for the treatment of inflammation |
| 01/29/2004 | CA2492862A1 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 01/29/2004 | CA2492805A1 Megasphaera elsdenii strain and its uses |
| 01/29/2004 | CA2492665A1 Azaindole kinase inhibitors |
| 01/29/2004 | CA2492651A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 01/29/2004 | CA2492598A1 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/29/2004 | CA2492110A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 01/29/2004 | CA2491131A1 Novel compounds as histone deacetylase inhibitors |
| 01/29/2004 | CA2466288A1 Methods of treating conditions associated with an edg-1 receptor |
| 01/28/2004 | EP1384721A1 Stable amorphous calcium pseudomonate and processes for the preparation thereof |
| 01/28/2004 | EP1384485A1 Bactericidal/permeability increasing protein or biologically active analogs thereof to treat lipopolysaccharide associated gram negative infections |
| 01/28/2004 | EP1384483A1 Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function |
| 01/28/2004 | EP1384479A1 Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications |
| 01/28/2004 | EP1384478A1 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
| 01/28/2004 | EP1384081A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 01/28/2004 | EP1383931A1 Nucleic acid vaccines for prevention of flavivirus infection |
| 01/28/2004 | EP1383927A2 New polynucleotides and polypeptides of the erythropoietin gene |
| 01/28/2004 | EP1383919A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383892A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/28/2004 | EP1383872A2 Genetically modified yt cell line and use thereof |
| 01/28/2004 | EP1383798A2 Transporters and ion channels |
| 01/28/2004 | EP1383795A2 A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine |
| 01/28/2004 | EP1383794A2 Daptomycin and related analogs in crystalline form, thier preparation and use |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383780A1 Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives |
| 01/28/2004 | EP1383778A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 01/28/2004 | EP1383764A1 Ratjadone derivatives for inhibiting cell growth |
| 01/28/2004 | EP1383762A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same |
| 01/28/2004 | EP1383750A2 Urea derivatives as integrin alpha 4 antagonists |